Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Shannon Life Sciences is a venture capital firm founded in Watertown, Massachusetts, with a dedicated focus on neuroscience. The firm provides early-stage strategic capital and expert guidance to entrepreneurs and researchers in the healthcare sector. Established to address the growing need for investment in neuroscience, Shannon Life Sciences aims to support groundbreaking technologies and treatments that can significantly impact healthcare outcomes.
Currently, the firm operates with a small team and has made one notable acquisition, Elm Street Labs, a lab infrastructure property in Watertown, MA. This acquisition serves as an operational platform to support local neuroscience startups. The firm is strategically embedded in the Boston life sciences community, which enhances its ability to connect with emerging companies in the sector.
Shannon Life Sciences focuses on early-stage investments, primarily in the pre-seed, seed, and seed-plus stages. The firm is actively building its team, seeking individuals with strong scientific backgrounds to enhance its investment capabilities. While specific metrics such as assets under management or fund size are not publicly disclosed, the firm’s commitment to neuroscience innovation is evident in its operational model.
Shannon Life Sciences specializes in investing in early-stage companies that are developing revolutionary ideas in neuroscience. The firm targets investments in the pre-seed, seed, and seed-plus stages, primarily within the healthcare and biotech sectors. Their investment strategy emphasizes supporting technologies and treatments that have the potential to transform healthcare outcomes.
The firm seeks to partner with entrepreneurs and researchers who are working on innovative solutions in neuroscience. Shannon Life Sciences looks for groundbreaking ideas that can significantly impact patient care and enhance lives. Their focus on early-stage investments allows them to provide not only capital but also strategic guidance to help startups navigate the complexities of the healthcare landscape.
Geographically, Shannon Life Sciences operates primarily in North America, with a strong emphasis on the Boston area, which is known for its vibrant life sciences community. This geographic focus enables the firm to leverage local resources and networks to support its portfolio companies effectively.
Shannon Life Sciences has made one significant acquisition to date: Elm Street Labs. This property, located in Watertown, MA, serves as a lab infrastructure platform designed to support local neuroscience startups. The acquisition was completed in 2024 for approximately $55 million and is part of the firm’s strategy to embed itself within the Boston life sciences community.
While no therapeutic portfolio companies have been disclosed, the firm’s ownership of Elm Street Labs positions it uniquely to foster the development of neuroscience innovations. This operational platform allows Shannon Life Sciences to provide essential resources and support to emerging companies in the neuroscience sector.
Gayle Gao - Managing Director. Gayle has extensive experience in venture capital and a strong background in healthcare investments. She has been instrumental in shaping the firm’s investment strategy.
Spencer Kimber - Investment Principal. Spencer has a background in real estate and venture capital, contributing to the firm’s unique hybrid model of investing and lab infrastructure ownership.
Hermann Liu - Investment Advisor. Hermann brings expertise in neuroscience and healthcare, providing valuable insights into the firm’s investment decisions.
Jenna Hester - Office Administrator. Jenna supports the operational aspects of the firm, ensuring smooth administrative processes.
To pitch Shannon Life Sciences, founders should send an email to contact@ystsls.com. It is important to include a comprehensive pitch deck that outlines the business model, market opportunity, and team qualifications. The firm does not publicly disclose specific response time expectations, but prompt and clear communication is advisable.
Warm introductions are beneficial, especially from individuals within the Boston life sciences community, as they can enhance credibility and facilitate connections with the firm.
In 2024, Shannon Life Sciences acquired Elm Street Labs in Watertown, MA from The Triad Group for approximately $55 million. This acquisition is primarily a lab infrastructure investment, enhancing the firm’s operational capabilities to support local neuroscience startups.
As of now, no additional therapeutic portfolio companies have been disclosed, and the firm continues to focus on building its presence in the Boston life sciences community.
What are the investment criteria for Shannon Life Sciences?
Shannon Life Sciences focuses on early-stage investments in neuroscience, specifically targeting pre-seed, seed, and seed-plus stages. The firm seeks companies developing innovative healthcare solutions that can significantly impact patient care.
How can founders apply or pitch to Shannon Life Sciences?
Founders can reach out to Shannon Life Sciences via email at contact@ystsls.com. It is advisable to include a detailed pitch deck outlining the business model, market opportunity, and team background.
What makes Shannon Life Sciences different from other venture capital firms?
Shannon Life Sciences combines traditional venture capital investing with ownership of lab infrastructure, which is uncommon in the industry. This hybrid model allows them to provide both capital and operational support to neuroscience startups.
What is the geographic scope of Shannon Life Sciences?
The firm primarily operates in North America, with a strong focus on the Boston area, which is known for its life sciences ecosystem.
What is the firm's post-investment involvement like?
Shannon Life Sciences provides expert guidance and strategic support to its portfolio companies, leveraging its lab infrastructure to assist in the development of neuroscience innovations.
What is the typical check size for investments?
While specific check sizes are not disclosed, Shannon Life Sciences focuses on early-stage investments, which typically range from pre-seed to seed-plus funding rounds.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.